Wilkinson: What is the Deal with Esketamine?
Samuel Wilkinson, MD, Assistant Professor of Psychiatry and Assistant Director of the Yale Depression Research Program, writes in Psychiatric Times about the drug esketamine, approved by the U.S. Food and Drug Administration last year as the first rapid-acting therapy for treatment-resistant depression.
Wilkinson Honored with New Investigator Award from ISCTM
Samuel Wilkinson, MD, Assistant Professor of Psychiatry and Assistant Director of the Yale Depression Research Program, has been awarded a New Investigator Award from the International Society of CNS Clinical Trials and Methodology (ISCTM).
New depression drug related to ketamine recommended by FDA panel
Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry; Director of the Yale Depression Research Program; and Co-Director of the Yale New Haven Hospital Interventional Psychiatry Service is featured in a NBC Nightly News report about the drug esketamine.
Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale Psychiatric Hospital
Yale researchers, including first author Samuel Wilkinson, MD, Assistant Professor of Psychiatry, describe in a paper published in Biological Psychiatry their experience providing ketamine as a clinical treatment to participants with severe and treatment-resistant mood disorders.
Depression treatments inspired by ketamine move ahead in tests
Antidepressant drugs that work in hours instead of weeks could be on the market within three years, researchers say. "I think it's highly probable that we'll see some version of one of these treatments being approved in the relatively near future," says Dr. Gerard Sanacora, director of the Yale Depression Research Program.
Suicide prevention and ketamine
Suicide, a significant public health problem, is closely linked with mental health conditions, especially depression. At the Yale Depression Research Clinic, a clinical trial is now underway to determine whether esketamine, a form of the drug ketamine, can help prevent suicide in depressed patients.
New drug shows same antidepressant effect as ketamine, study shows
A drug under development seems to have similar antidepressant effects as previously observed with ketamine, but without the same level of dangerous side effects seen when the anesthetic is abused as a party drug, according to a new Yale-led study. Gerard Sanacora, MD, PhD, professor of psychiatry and director of the Yale Depression Research Program, is first author.
Yale Researchers Find Where Stress Lives
Yale researchers have found a neural home of the feeling of stress people experience, an insight that may help people deal with the debilitating sense of fear and anxiety that stress can evoke, Yale researchers report May 27 in the journal Nature Communications.
Updates in Consultation-Liaison Psychiatry: 2019
Paula Zimbrean, MD, Associate Professor of Psychiatry; Walter Luchsinger, MD, Addiction Psychiatry Fellow; and Jordan Rosen, MD, Consultation-Liaison Psychiatry Fellow, are co-authors of a paper published in Psychosomatics that identifies the 10 most important manuscripts for clinical practice in consultation-liaison psychiatry from 2019.
Courses of Suicidal Ideation Among Military Veterans in Residential Treatment for Posttraumatic Stress Disorder
Noelle B. Smith, PhD, Assistant Clinical Professor of Psychiatry; Rani Hoff, PhD, Professor of Psychiatry; and Ilan Harpaz-Rotem, PhD, are co-authors of a study published in Depression & Anxiety that examines the prevalence and correlates of four courses of suicidal ideation among veterans receiving residential treatment for posttraumatic stress disorder.
Psilocybin-Assisted Therapy of Major Depressive Disorder Using Acceptance and Commitment Therapy as a Therapeutic Frame
Jordan Sloshower, MD, MSc, Research Fellow in Addiction Psychiatry, is the first author of a paper published in Journal of Contextual Behavioral Science that tracks the psychedelic assisted therapy of depression with the integration of Acceptance and Commitment Therapy.
Delayed Homelessness After Military Discharge: Examination of a Sleeper Effect
Jack Tsai, PhD, Adjunct Associate Professor of Psychiatry, and Robert Pietrzak, PhD, Associate Professor of Psychiatry and Public Health, are the first and senior authors, respectively, published in American Journal of Preventive Medicine that examines the “sleeper effect” of longer discharge-to-homelessness periods for veterans including service in the Vietnam War, younger age at military discharge, and chronic medical conditions, depression, and alcohol use problems.
Ni Feng receives a 2020 Warren Alpert Distinguished Scholar Award
Ni Fend, a postdoctoral researcher in Elena Gracheva's lab, has become a 2020 Warren Alpert Distinguished Scholar. Her project "Hanging in the Balance: Fluid Homeostasis in Hibernation" aims to reveal fundamental knowledge about how hibernation enables some species to survive over an entire winter without water. This project will use the thirteen-lined ground squirrel as a model system to dissect and manipulate the neural circuits that regulate fluid balance across torpor and arousal states during hibernation.